Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Moderna, Inc. (MRNA) has a Wall Street consensus price target of $34.89, based on estimates from 27 covering analysts. With the stock currently trading at $53.57, this represents a potential downside of -34.9%. The company has a market capitalization of $20.95B.
Analyst price targets range from a low of $17.00 to a high of $63.00, representing a 132% spread in expectations. The median target of $30.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 8 analysts rating the stock as a Buy or Strong Buy,15 rating it Hold, and 4 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, MRNA trades at a trailing P/E of -5.8x. Analysts expect EPS to grow +19.2% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how MRNA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonMRNA's consensus price target is $34.89, -34.9% below the current price of $53.57. The 27 analysts tracking MRNA see downside risk at present valuations.
MRNA has a consensus rating of "Hold" based on 27 Wall Street analysts. The rating breakdown is mixed, with 15 Hold ratings making up the largest segment. The consensus 12-month price target of $34.89 implies -34.9% downside from current levels.
MRNA's current price is $53.57 with a consensus target of $34.89 (-34.9% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $63 for MRNA, while the most conservative target is $17. The consensus of $34.89 represents the median expectation. These targets typically reflect 12-month expectations.
MRNA is heavily covered by Wall Street, with 27 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 15 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MRNA stock forecast based on 27 Wall Street analysts shows a consensus price target of $34.89, with estimates ranging from $17 (bear case) to $63 (bull case). The median consensus rating is "Hold".
Analysts are cautious on MRNA, with 4 Sell ratings and a price target of $34.89 (-34.9% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MRNA analyst price targets range from $17 to $63, a 132% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $34.89 consensus represents the middle ground.